• Quick Order

Pseudomonas aeruginosa (Schroeter) Migula


Download Genome Learn about our Enhanced Authentication Initiative
Pseudomonas aeruginosa strain PGO2338 is a whole-genome sequenced, multidrug-resistant strain isolated from a human sputum sample. It was collected from a cystic fibrosis patient during a Phase III clinical trial that tested the effectiveness of aerosolized Tobi (Tobramycin). It has applications in antimicrobial resistance research and drug development.
Product category
Product type
Drug-resistant bacterium
Strain designation
Type strain
Genome sequenced strain
Isolation source
Sputum sample
Antimicrobial resistance research
Drug development
Product format
Storage conditions
-80°C or colder
Buy Now
Price: $431.00 EA
Discounts may be available for our fellow nonprofit organizations. Login to see your price.

Generally ships within 1-3 business days


ATCC determines the biosafety level of a material based on our risk assessment as guided by the current edition of Biosafety in Microbiological and Biomedical Laboratories (BMBL), U.S. Department of Health and Human Services. It is your responsibility to understand the hazards associated with the material per your organization’s policies and procedures as well as any other applicable regulations as enforced by your local or national agencies.

ATCC highly recommends that appropriate personal protective equipment is always used when handling vials. For cultures that require storage in liquid nitrogen, it is important to note that some vials may leak when submersed in liquid nitrogen and will slowly fill with liquid nitrogen. Upon thawing, the conversion of the liquid nitrogen back to its gas phase may result in the vial exploding or blowing off its cap with dangerous force creating flying debris. Unless necessary, ATCC recommends that these cultures be stored in the vapor phase of liquid nitrogen rather than submersed in liquid nitrogen.

Detailed product information


Specific applications
This strain of Pseudomonas aeruginosa is multidrug-resistant.


Susceptibility profile


This isolate was collected from a sputum sample of a cystic fibrosis patient during a Phase III clinical trial that tested the effectiveness of aerosolized Tobi (Tobramycin). The 1995-1996 clinical trial was conducted by a consortium led by Chiron and later acquired by Novartis AG.
Multidrug resistant

Handling information

Handling procedure
  1. Just prior to inoculation place the frozen vial at room temperature to thaw. 
  2. Transfer the entire contents of the vial to a tube of #18 broth (5 to 6 mL).
  3. Use several drops of the cell suspension to inoculate a #18 agar slant and/or plate.  Additional #18 broth tubes may be inoculated by transferring 0.5 mL of the primary tube to each addition broth tube. 
  4. Incubate the tubes and plate at 37°C for 24 hours.
Handling notes
This strain of Pseudomonas aeruginosa is a multidrug-resistant strain that was isolated from a clinical drug trial for cystic fibrosis patients. 

Additional information on this culture is available on the ATCC® web site at

Quality control specifications

Verification method
Whole-genome Sequencing


Type of isolate

Legal disclaimers

Intended use
This product is intended for laboratory research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use.

The product is provided 'AS IS' and the viability of ATCC® products is warranted for 30 days from the date of shipment, provided that the customer has stored and handled the product according to the information included on the product information sheet, website, and Certificate of Analysis. For living cultures, ATCC lists the media formulation and reagents that have been found to be effective for the product. While other unspecified media and reagents may also produce satisfactory results, a change in the ATCC and/or depositor-recommended protocols may affect the recovery, growth, and/or function of the product. If an alternative medium formulation or reagent is used, the ATCC warranty for viability is no longer valid.  Except as expressly set forth herein, no other warranties of any kind are provided, express or implied, including, but not limited to, any implied warranties of merchantability, fitness for a particular purpose, manufacture according to cGMP standards, typicality, safety, accuracy, and/or noninfringement.


This product is intended for laboratory research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. Any proposed commercial use is prohibited without a license from ATCC.

While ATCC uses reasonable efforts to include accurate and up-to-date information on this product sheet, ATCC makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. ATCC does not warrant that such information has been confirmed to be accurate or complete and the customer bears the sole responsibility of confirming the accuracy and completeness of any such information.

This product is sent on the condition that the customer is responsible for and assumes all risk and responsibility in connection with the receipt, handling, storage, disposal, and use of the ATCC product including without limitation taking all appropriate safety and handling precautions to minimize health or environmental risk. As a condition of receiving the material, the customer agrees that any activity undertaken with the ATCC product and any progeny or modifications will be conducted in compliance with all applicable laws, regulations, and guidelines. This product is provided 'AS IS' with no representations or warranties whatsoever except as expressly set forth herein and in no event shall ATCC, its parents, subsidiaries, directors, officers, agents, employees, assigns, successors, and affiliates be liable for indirect, special, incidental, or consequential damages of any kind in connection with or arising out of the customer's use of the product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, ATCC is not liable for damages arising from the misidentification or misrepresentation of such materials.

Please see the material transfer agreement (MTA) for further details regarding the use of this product. The MTA is available at

Permits & Restrictions

Import Permit for the State of Hawaii

If shipping to the U.S. state of Hawaii, you must provide either an import permit or documentation stating that an import permit is not required. We cannot ship this item until we receive this documentation. Contact the Hawaii Department of Agriculture (HDOA), Plant Industry Division, Plant Quarantine Branch to determine if an import permit is required.



Curated Citations

Ramsey BW, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 328(24): 1740-1746, 1993. PubMed: 8497284

Burns JL, et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin. Infect. Dis. 27(1): 158-163, 1998. PubMed: 9675470

Burns JL, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis. 179(5): 1190-1196, 1999. PubMed: 10191222

Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest. 120(3 Suppl): 107S-113S, 2001. PubMed: 11555564

Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest. 121(1): 55-63, 2002. PubMed: 11796432

Frequently Asked Questions

Need assistance with this product? Contact our Technical Support team.



US and Puerto Rico

Outside the US

Hours of Operation

9:30am - 5:30pm
US Eastern Time